Apremilast for genital erosive lichen planus in women (the AP-GELP Study): study protocol for a randomised placebo-controlled clinical trial.
Apremilast
Genital erosive lichen planus
Phosphodiesterase-4 inhibitor
Randomised clinical trial
Vulval disease
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
20 Jul 2021
20 Jul 2021
Historique:
received:
25
10
2020
accepted:
06
07
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial. We will recruit 42 adult women with characteristic clinical and/or histological features of moderate-to-severe GELP from a specialised vulva clinic in Oslo, Norway. The patients will be randomised 1:1 to either apremilast 30 mg BID (with an initial dose titration on days 1-6) or a placebo for 24 weeks. The concomitant use of topical corticosteroids will be allowed. The primary end point will be the mean GELP score, a clinical scoring system, at week 24 in the apremilast-treated patients versus the placebo-treated patients. The secondary end points will include the mean GELP score improvement from weeks 0 to 24, patient-reported use of topical steroids, the pain score on a visual analogue scale and the number of patients with GELP score improvements at weeks 16 and 24. The Physician Global Assessment , Patient Global Assessment and selected quality of life and sexual function assessments will be recorded at weeks 0, 16 and 24. The exploratory endpoints include description of immunohistochemical changes before and after apremilast therapy, assessed in vulvar or vaginal biopsies at weeks 0 and 24. Regular follow-ups for possible adverse events will be conducted. The study design is based on experience from studies on apremilast in other inflammatory skin diseases using equivalent apremilast doses for approved indications. The trial may provide evidence for the use of apremilast in women with this burdensome genital dermatosis. ClinicalTrials.gov NCT0365666 . Registered on 4 September 2018.
Sections du résumé
BACKGROUND
BACKGROUND
Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial.
METHODS
METHODS
We will recruit 42 adult women with characteristic clinical and/or histological features of moderate-to-severe GELP from a specialised vulva clinic in Oslo, Norway. The patients will be randomised 1:1 to either apremilast 30 mg BID (with an initial dose titration on days 1-6) or a placebo for 24 weeks. The concomitant use of topical corticosteroids will be allowed. The primary end point will be the mean GELP score, a clinical scoring system, at week 24 in the apremilast-treated patients versus the placebo-treated patients. The secondary end points will include the mean GELP score improvement from weeks 0 to 24, patient-reported use of topical steroids, the pain score on a visual analogue scale and the number of patients with GELP score improvements at weeks 16 and 24. The Physician Global Assessment , Patient Global Assessment and selected quality of life and sexual function assessments will be recorded at weeks 0, 16 and 24. The exploratory endpoints include description of immunohistochemical changes before and after apremilast therapy, assessed in vulvar or vaginal biopsies at weeks 0 and 24. Regular follow-ups for possible adverse events will be conducted.
DISCUSSION
CONCLUSIONS
The study design is based on experience from studies on apremilast in other inflammatory skin diseases using equivalent apremilast doses for approved indications. The trial may provide evidence for the use of apremilast in women with this burdensome genital dermatosis.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT0365666 . Registered on 4 September 2018.
Identifiants
pubmed: 34284808
doi: 10.1186/s13063-021-05428-w
pii: 10.1186/s13063-021-05428-w
pmc: PMC8290211
doi:
Substances chimiques
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
469Informations de copyright
© 2021. The Author(s).
Références
Acta Obstet Gynecol Scand. 2010 Jul;89(7):966-70
pubmed: 20583940
Health Qual Life Outcomes. 2013 May 10;11:82
pubmed: 23663752
J Dermatolog Treat. 2020 Mar;31(2):131-140
pubmed: 30935262
J Am Acad Dermatol. 2013 Feb;68(2):255-61
pubmed: 22910104
J Dermatol. 2015 Mar;42(3):311-4
pubmed: 25583369
Br J Dermatol. 2015 Nov;173(5):1156-62
pubmed: 26189484
Drugs. 2017 Mar;77(4):459-472
pubmed: 28213862
Br J Dermatol. 2013 Aug;169(2):337-43
pubmed: 23521206
JAMA Dermatol. 2015 Apr;151(4):375-81
pubmed: 25549367
Arch Dermatol. 2012 Aug;148(8):890-7
pubmed: 22508772
Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):214-9
pubmed: 24183096
Br J Dermatol. 2015 Dec;173(6):1387-99
pubmed: 26357944
Dermatol Ther. 2004;17(1):38-46
pubmed: 14756889
J Am Acad Dermatol. 2015 Jul;73(1):37-49
pubmed: 26089047
Case Rep Dermatol. 2016 Aug 29;8(2):224-226
pubmed: 27721755
N Engl J Med. 2015 Apr 16;372(16):1510-8
pubmed: 25875256
Clin Exp Dermatol. 2005 Sep;30(5):551-6
pubmed: 16045691
Obstet Gynecol Clin North Am. 2017 Sep;44(3):407-420
pubmed: 28778640
J Eur Acad Dermatol Venereol. 2006 Jul;20(6):661-6
pubmed: 16836492
N Engl J Med. 2019 Nov 14;381(20):1918-1928
pubmed: 31722152
Arthritis Res Ther. 2015 Sep 15;17:249
pubmed: 26370839
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008092
pubmed: 22336835
J Low Genit Tract Dis. 2018 Oct;22(4):405-408
pubmed: 29975332
Semin Cutan Med Surg. 2015 Dec;34(4):182-6
pubmed: 26650696
Trials. 2016 Jan 04;17:2
pubmed: 26729245
BMC Med. 2013 Apr 04;11:96
pubmed: 23557064
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
J Sex Marital Ther. 2002 Jul-Sep;28(4):317-30
pubmed: 12082670
Br J Dermatol. 2002 Sep;147(3):625-6
pubmed: 12207624
J Drugs Dermatol. 2016 Aug 1;15(8):1026-8
pubmed: 27538007
J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963
pubmed: 28895202
J Am Acad Dermatol. 2017 Aug;77(2):310-317.e1
pubmed: 28416342
J Low Genit Tract Dis. 2017 Apr;21(2):145-149
pubmed: 27906807
J Dermatol Case Rep. 2016 Nov 30;10(3):56-57
pubmed: 28400896
N Engl J Med. 2019 Nov 14;381(20):1975-1977
pubmed: 31722161
Cell Signal. 2016 Jul;28(7):753-63
pubmed: 26806620
Clin Exp Dermatol. 2016 Aug;41(6):684-5
pubmed: 27339859
Psychol Med. 1979 Feb;9(1):139-45
pubmed: 424481